Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Cathie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Mice with two fathers have been born — and have survived to adulthood — following a complex set of experiments by a team in China.

NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...